Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Summary

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Timeline

Start

2026-08-18

Primary completion

2027-10

Completion

2028-04

Drugs

Indications